Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days
each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour
prior to or two hours after meals. Patients will be evaluated after 1 full cycle of therapy
(28 days).